PMC:7200337 / 91632-91877
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T723 | 101-109 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T523 | 177-185 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T524 | 186-189 | Disease | denotes | CRS | http://purl.obolibrary.org/obo/MONDO_0007399|http://purl.obolibrary.org/obo/MONDO_0017361 |
| T526 | 194-203 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T957 | 145-151 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T290 | 20-22 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T292 | 37-48 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T293 | 96-98 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T55 | 194-203 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T204 | 20-25 | http://purl.obolibrary.org/obo/GO_0004915 | denotes | IL-6R |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 3026 | 20-25 | Gene | denotes | IL-6R | Gene:3570 |
| 3027 | 96-100 | Gene | denotes | IL-6 | Gene:3569 |
| 3035 | 37-48 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 3036 | 63-72 | Chemical | denotes | sarilumab | MESH:C000592401 |
| 3037 | 74-81 | Chemical | denotes | Kevzara | MESH:C000592401 |
| 3044 | 177-185 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 3045 | 194-203 | Disease | denotes | pneumonia | MESH:D011014 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T521 | 0-245 | Sentence | denotes | The commercial anti-IL-6R antibodies tocilizumab (Actemra) and sarilumab (Kevzara) and the anti-IL-6 antibody siltuximab (Sylvant) are now being tested for efficacy in managing COVID-19 CRS and pneumonia in 13 ongoing clinical trials (Table 2 ). |